Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "protein"

572 News Found

Viva Biotech supercharges AI-driven drug discovery with NVIDIA tech
R&D | March 20, 2026

Viva Biotech supercharges AI-driven drug discovery with NVIDIA tech

The move aims to accelerate drug discovery with AI-driven designs powered by NVIDIA technology


IIT Roorkee unveils cutting-edge molecular medicine facility
R&D | March 19, 2026

IIT Roorkee unveils cutting-edge molecular medicine facility

The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics


GSK expands RSV vaccine to younger adults in US, targeting high-risk 18–49 age group
News | March 16, 2026

GSK expands RSV vaccine to younger adults in US, targeting high-risk 18–49 age group

Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk


Almirall opens Shanghai hub to power dermatology innovation and China partnerships
Biopharma | March 14, 2026

Almirall opens Shanghai hub to power dermatology innovation and China partnerships

The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development


Meiji Seika Pharma launches first-in-human trial of Novel PD-1 agonist for autoimmune diseases
Clinical Trials | March 14, 2026

Meiji Seika Pharma launches first-in-human trial of Novel PD-1 agonist for autoimmune diseases

The early-stage study will test the drug’s safety, tolerability and biological effects in humans


MetaVia locks down global patent shield for metabolic drug candidate Vanoglipel
Biotech | March 14, 2026

MetaVia locks down global patent shield for metabolic drug candidate Vanoglipel

The protections extend through at least 2035, with the potential for further extensions


Vertex Pharmaceuticals’ new kidney drug shows dramatic results in Phase 3 trial
Clinical Trials | March 12, 2026

Vertex Pharmaceuticals’ new kidney drug shows dramatic results in Phase 3 trial

The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36


Bristol Myers Squibb reports positive phase 3 results for oral multiple myeloma therapy
Clinical Trials | March 10, 2026

Bristol Myers Squibb reports positive phase 3 results for oral multiple myeloma therapy

The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen


FDA nod to groundbreaking combo therapy for relapsed multiple myeloma
News | March 07, 2026

FDA nod to groundbreaking combo therapy for relapsed multiple myeloma

This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile